Benefits
Acute ischemic stroke (2024 meta-analysis)
(2024 meta-analysis) followed PRISMA guidelines with GRADE evidence quality assessment and RoB 2.0 risk-of-bias evaluation. Lumbrokinase improved neurological function and reduced laboratory markers of thrombosis in acute ischemic stroke alongside supportive care. Important framing: this is adjunctive evidence, not a replacement for alteplase or other established stroke therapy. The included trials were predominantly Chinese with methodological limitations the meta-analysis itself acknowledges.
Secondary ischemic stroke prevention
Cao YJ et al. 2013 (Chin Med J 126:4060-4065) — multicenter randomized parallel-group controlled clinical trial for secondary ischemic stroke prevention via oral fibrinogen-depleting agent. Foundational Chinese multicenter evidence. Should be discussed with a neurologist before use in any patient with prior stroke given the bleeding-risk profile of fibrinolytic agents.
Cerebral infarct hemostasis modulation (Jin et al.)
Jin et al. — 51 cerebral infarct subjects, lumbrokinase 3 × 400 mg/day for 28 days. KPTT prolonged, tPA activity and D-dimer increased, fibrinogen decreased significantly. Mechanistic confirmation that oral lumbrokinase produces measurable changes in hemostasis parameters.
Diabetic foot ulcer healing (Rey et al.)
Rey et al. — 28 diabetic foot ulcer subjects, lumbrokinase 3 × 500 mg/day for 7 days. Fibrinolytic activity improvements observed. Small emerging application; sample size and duration limit conclusions.
DLBS1033 hemostasis healthy volunteers
DLBS1033 is the Indonesian commercial form. — healthy-volunteer hemostasis trial reported fibrinogenolytic activities on fibrinogen α/β/γ chains, decreased platelet aggregation, and prolonged clotting time. Adds non-Chinese geographic generalizability to the lumbrokinase evidence base.
DLBS1033 acute ischemic stroke RCT
— DLBS1033 add-on therapy in acute ischemic stroke at Bethesda Hospital Yogyakarta, Indonesia. Indonesian/Western evidence supplementing the predominantly Chinese trial base.
Preclinical cardioprotection
Wang 2018 (Front Pharmacol 9:636) — Sirt1 activation and post-ischemic cardioprotection in animal models. Wang 2016 (J Mol Cell Cardiol 99:113-122) — TLR4 signaling inhibition with cardioprotective effects. Preclinical mechanistic findings; not yet translated to clinical cardiovascular endpoints.
Mechanism of action
Direct fibrinolysis (fibrin-specific)
Lumbrokinase directly degrades fibrin with specificity that exceeds nattokinase's broader proteolytic activity. The fibrin-specificity is the distinguishing pharmacological feature — favorable for the bleeding-risk profile compared to non-specific systemic fibrinolytics.
Indirect fibrinolysis via tPA / plasminogen activation
Lumbrokinase enhances endogenous fibrinolysis by promoting tissue plasminogen activator (tPA) activity and plasminogen-to-plasmin conversion. Indirect mechanism amplifying the body's own fibrinolytic system.
Six-enzyme group (Cho 2004 + Mihara 1991 characterization)
Mihara 1991 (PMID 1960890, Jpn J Physiol 41:461-472) is the foundational characterization paper. Cho 2004 (J Biochem Mol Biol 37:199-205) purified and characterized six fibrinolytic serine proteases — abundant asparagine/aspartic acid and minimal proline/lysine, distinguishing the compositional profile from typical serine proteases.
Higher thermal stability and alkali resistance
Lumbrokinase shows higher thermal and alkali stability than urokinase, streptokinase, or tPA — the property that makes oral administration viable. Without these stability features, the enzyme would be destroyed by gastric processing before reaching circulation.
Does not directly convert plasminogen to plasmin
Unlike streptokinase or urokinase, lumbrokinase does not directly activate systemic plasminogen. This contributes to the lower bleeding-risk profile vs systemic fibrinolytics — though the safety advantage is relative, not absolute.
TLR4 signaling inhibition (preclinical)
Wang 2016 — preclinical evidence that lumbrokinase inhibits TLR4 signaling, contributing to anti-inflammatory and cardioprotective effects in animal models. Mechanistic rationale that has not yet been confirmed in clinical trials.
Sirt1 activation (preclinical)
Wang 2018 — preclinical evidence of Sirt1 pathway activation contributing to post-ischemic cardioprotection. Animal-model finding pending human translation.
Clinical trials
2024 meta-analysis following PRISMA guidelines with GRADE evidence quality assessment and RoB 2.0 risk-of-bias evaluation. Lumbrokinase improved neurological function and reduced laboratory thrombosis markers in acute ischemic stroke alongside supportive care. The most rigorous evidence summary for the ingredient — but included trials are predominantly Chinese with methodological limitations.
Cao YJ et al. 2013, Chin Med J 126:4060-4065. Multicenter randomized parallel-group controlled clinical trial for secondary ischemic stroke prevention via oral fibrinogen-depleting agent. Foundational Chinese multicenter evidence; methodological limitations acknowledged in subsequent meta-analyses.
Jin et al. — 51 cerebral infarct subjects, lumbrokinase 3 × 400 mg/day for 28 days. KPTT prolonged, tPA activity and D-dimer increased, fibrinogen decreased significantly. Mechanistic confirmation of oral lumbrokinase effects on hemostasis parameters.